Related Experiment Video
Updated: Dec 13, 2025
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin
Abstract:
Lefamulin is a novel systemic, semi-synthetic pleuromutilin class of antimicrobials that has been shown to be effective against common respiratory pathogens associated with community-acquired bacterial pneumonia (CABP). CABP, a common infection among older people, leads to an increase in hospitalizations and mortality. Therefore, the use of lefamulin could be beneficial for CABP treatment in patients who are 65 years of age or older.
The Food and Drug Administration (FDA) approved lefamulin for the treatment of CABP, which is available in both intravenous and oral formulations. This medication offers the benefit of not having any cross-resistance to other antibiotics and is highly concentrated in lung tissues. Lefamulin is unique because it has an induced-fit mechanism of action which inhibits bacterial protein synthesis. The clinical efficacy of lefamulin has demonstrated noninferiority to current standard-of-care for CABP, and patients, generally, have tolerated it well in clinical trials.
Lefamulin does not require dosage adjustment in renal impairment. However, the drug does requires dosage adjustment in severe hepatic impairment, based on Child-Pugh scores and clinical consideration in patients with severe hepatic impairment based on Child-Pugh scores. Though the benefit of adding lefamulin to a formulary is still in question; its potential to be a beneficial treatment for CABP is encouraging.
Insights
Lefamulin is a new antibiotic effective against community-acquired bacterial pneumonia (CABP). It shows non-inferiority to standard treatments and is well-tolerated, offering a new option for CABP patients.
Area of Science:
- Pharmacology
- Infectious Diseases
- Respiratory Medicine
Background:
- Community-acquired bacterial pneumonia (CABP) is a significant cause of hospitalization and mortality, particularly in older adults.
- Novel antimicrobial agents are needed to combat resistant pathogens and provide effective treatment options.
- Lefamulin represents a new class of antibiotics targeting common CABP pathogens.
Purpose of the Study:
- To evaluate the efficacy and safety of lefamulin for treating community-acquired bacterial pneumonia (CABP).
- To assess lefamulin's potential as a treatment option for patients with CABP, including those aged 65 and older.
Main Methods:
- Clinical trials were conducted to assess the efficacy of lefamulin compared to standard-of-care treatments for CABP.
- Pharmacokinetic properties, including dosage adjustments for renal and hepatic impairment, were evaluated.
- Safety and tolerability profiles were monitored in patient populations.
Main Results:
- Lefamulin demonstrated non-inferiority to current standard-of-care for CABP treatment.
- The drug is well-tolerated by patients in clinical trials.
- Lefamulin exhibits a unique induced-fit mechanism of action, inhibiting bacterial protein synthesis without cross-resistance.
Conclusions:
- Lefamulin is an effective and well-tolerated treatment option for CABP.
- It offers a novel mechanism of action and is a promising alternative for CABP management.
- Dosage adjustment is not required for renal impairment but is necessary for severe hepatic impairment.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:27Acute Pyelonephritis I: Introduction
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....